Meldonium

Mildronate

Meldonium (Mildronate) is a metabolic & fat loss research compound. Inhibits carnitine biosynthesis/transport — shifts heart and muscle toward glucose oxidation, improving oxygen efficiency and endurance under stress/ischemia.

How Meldonium works

Inhibits carnitine biosynthesis/transport — shifts heart and muscle toward glucose oxidation, improving oxygen efficiency and endurance under stress/ischemia.

Proposed benefits

Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.

Where to get Meldonium

The evidence for Meldonium

Graded by what exists behind each claim.

Human clinical evidence

• The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.

📊 Correlative data

• The most famous doping case of the last decade — it was added to the WADA prohibited list in 2016 and immediately produced a wave of positive tests across Eastern European sport, revealing just how widespread its use had been.
• Registered in Latvia and used across the former Soviet bloc for angina and heart failure. The scale of athletic use is itself a data point about perceived effect, though it says nothing about magnitude.

🧪 Theoretical / extrapolated

• Inhibits gamma-butyrobetaine hydroxylase, reducing carnitine synthesis, and blocks carnitine transport into cells. Less carnitine means less fatty acid transported into mitochondria, forcing a shift toward glucose oxidation.
• Glucose oxidation yields more ATP per unit of oxygen than fat oxidation, which is the entire rationale: under ischemia or maximal effort, oxygen is the constraint, so the more oxygen-efficient fuel wins.
• The mechanism predicts its own limit. Anything that improves performance specifically when oxygen-limited should do little when it is not — and deliberately impairing fat oxidation is the opposite of what someone chasing fat loss wants.

How to read the Soviet clinical series →

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Meldonium actually does

Meldonium is 3-(2,2,2-trimethylhydrazinium)propionate, and its whole pharmacology is that it looks like gamma-butyrobetaine. Gamma-butyrobetaine is the immediate precursor of carnitine: the last step of carnitine biosynthesis is its hydroxylation by gamma-butyrobetaine hydroxylase. Meldonium replaces one carbon of that substrate with a nitrogen and stops being hydroxylatable. It is a substrate mimic that jams the last step of a biosynthetic pathway.

Two targets, both named. Gamma-butyrobetaine hydroxylase and the carnitine/organic cation transporter OCTN2 are the main known drug targets, and the pharmacological effect is described as regulation of energy metabolism pathways through an L-carnitine lowering effect, whose decline stimulates glucose metabolism; the drug also reduces long-chain acylcarnitines and trimethylamine-N-oxide Dambrova 2016.

Those are two different ways to lower the same molecule. Inhibiting the hydroxylase stops carnitine being made. Inhibiting OCTN2 stops it being reabsorbed by the kidney and taken up into muscle and heart. Attacking synthesis and retention simultaneously is why a small molecule can meaningfully deplete a pool the body normally defends.

Why lowering carnitine changes what the heart burns. Long-chain fatty acids cannot cross the inner mitochondrial membrane on their own; they are esterified to carnitine, ferried across, and released inside. Drop the carrier and long-chain fatty acid oxidation falls, and the cell makes up the ATP from glucose instead. That substrate switch is the entire anti-ischemic rationale, and it has two separable benefits: glucose oxidation yields more ATP per mole of oxygen consumed than fatty acid oxidation, which matters when oxygen is the limiting supply; and the long-chain acylcarnitines that accumulate in ischemic tissue — detergent-like molecules that destabilize membranes and promote arrhythmia — are reduced Dambrova 2016.

And this is the rare case where the mechanism was measured directly in a living animal rather than inferred. Hyperpolarized magnetic resonance, which tracks the fate of labeled pyruvate in real time, showed that meldonium increased flux through pyruvate dehydrogenase 3.1-fold in diabetic rats and 1.2-fold in controls, with improved post-ischemic cardiac function Savic 2021. Pyruvate dehydrogenase is the gatekeeper committing glucose to oxidation, so that is the predicted substrate switch, seen happening, in vivo.

Note the two numbers, because they are the most useful thing on this page. 3.1-fold in the diabetic heart. 1.2-fold in the healthy one. The drug does most where fat dependence is greatest and least where metabolic flexibility is already intact Savic 2021. The population buying it for performance is the population its own mechanism predicts will respond least.

The TMAO arm, which is a separate story with a shared cause. Gut bacteria convert dietary carnitine to trimethylamine, and the liver oxidizes that to trimethylamine-N-oxide, a metabolite associated with cardiovascular risk. Lower the carnitine pool and TMAO falls Dambrova 2016. So one drug reduces a cardiovascular risk marker and reduces the body’s fat-transport capacity by the same action.

Cell, rodent, human — and where it stops

Step one, enzymology and transport. Gamma-butyrobetaine hydroxylase and OCTN2 as the two identified targets; carnitine, long-chain acylcarnitines and TMAO as the measurable consequences Dambrova 2016.

Step two, in rats, with the mechanism imaged rather than assumed. Type 1 diabetes induced with streptozotocin at 55 mg/kg in 36 male Wistar rats; meldonium at 100 mg/kg per day for three weeks; hyperpolarized magnetic resonance measuring cardiac pyruvate dehydrogenase flux in vivo. Flux rose 3.1-fold in the diabetic animals and 1.2-fold in controls, and post-ischemic function improved Savic 2021.

Step three, in rats, a different organ and a much bigger dose. Acute ischemia/reperfusion liver injury in male Wistar rats, with meldonium at 300 mg/kg of body mass daily as a four-week pre-treatment Đurašević 2021. The design is prophylactic: the drug was on board for a month before the insult, which is consistent with a mechanism that has to deplete a tissue pool before it does anything.

Step four, in humans, and here the record changes character. Meldonium is a licensed medicine in several Eastern European countries for ischemic heart disease and has been used clinically for decades. It has never been assessed by the FDA or the EMA, and the English-language indexed literature contains no large randomized outcome trial. What it does contain, prominently, is the doping story: since 2016 meldonium has been on the World Anti-Doping Agency’s S4 list Pușcaș 2024.

The dose gap, computed rather than waved at. The rodent doses are 100 mg/kg Savic 2021 and 300 mg/kg Đurašević 2021. Converting rat to human by the standard body-surface-area factor of about 6.2 gives human-equivalent doses of roughly 16 to 48 mg/kg — about 1.1 to 3.4 grams a day in a 70 kg adult. This site’s card lists 250 to 1,000 mg. So the human protocol sits at or below the bottom of the range that produced the published animal effects, and the two cannot be compared as though they were the same exposure.

The obstacles, one at a time. (1) The mechanistic proof is in a diabetic rat heart Savic 2021, and the effect in the non-diabetic control was 1.2-fold against 3.1 — barely a quarter of the response. (2) The human efficacy record is regional and not indexed to Western trial standards; approval in one jurisdiction is a real evidentiary position and it is not an outcome trial. (3) No randomized trial of exercise performance in healthy humans with a hard endpoint appears in the indexed record, which is remarkable for a compound famous for being banned in sport. (4) The animal work uses doses two to ten times the human protocol. (5) The liver study is a pre-treatment design Đurašević 2021, so it says nothing about taking the drug after an event.

Meldonium pharmacokinetics — how much of it actually gets in

The card says ~4–6 hours, and for this compound the plasma half-life is close to irrelevant. The number that governs it is the turnover time of the carnitine pool, which is measured in weeks.

What the molecule is, physically. A small zwitterion of about 146 Da carrying a permanent positive charge on the trimethyl-hydrazinium nitrogen and a carboxylate at the other end — the same architecture as carnitine and gamma-butyrobetaine themselves. It is far too polar to cross membranes passively in either direction, which is precisely why its distribution runs through the carnitine transporter it also inhibits Dambrova 2016. That is an unusual situation: the drug’s own uptake and its mechanism of action share a protein, so a person’s OCTN2 activity governs both how much drug enters a tissue and how much carnitine it loses.

What clears it. A small, highly polar, unbound cation is filtered at the glomerulus and handled by renal cation transport; there is no reason for extensive hepatic metabolism and none is described Dambrova 2016. Renal elimination of largely unchanged drug is the expectation, which also means kidney function is the variable that moves exposure.

Now the number that actually matters, and it is a pharmacodynamic one. Both rodent studies dosed for three weeks Savic 2021 and four weeks Đurašević 2021 before measuring anything. That is not caution; it is what the mechanism requires. The drug does not act on the heart — it lowers a metabolite pool, and a tissue carnitine pool is large, actively retained and slow to fall. The plasma half-life is hours and the pharmacodynamic time constant is weeks, in both directions.

Two consequences follow directly, and neither is on any protocol sheet. First, a short course does nothing: taking meldonium for a week and judging it is judging a drug that has not yet had time to change the quantity it works through. Second, stopping does not stop it — carnitine has to be re-synthesized and re-imported against the same slow kinetics, so the metabolic effect and the detectability of the compound both persist long after the last dose. That second point is the pharmacological explanation for why the 2016 listing Pușcaș 2024 caught so many athletes who believed they had stopped in time, and it is reasoning from the mechanism rather than a published excretion study.

The oral route, and why it works for a molecule this polar. Meldonium is given by mouth and is clearly absorbed. A permanently charged zwitterion has no passive route across the enterocyte, so absorption almost certainly uses the intestinal organic cation and carnitine transporters — the same family it inhibits. Treat that as an inference from the chemistry: no absolute bioavailability figure for meldonium appears in the papers read for this page.

What would have to be true, and how you would know it was not

Four predictions, and this is one of very few compounds in this catalog where the target-engagement marker is a test you can simply order.

1. Free and total carnitine should fall. This is direct target engagement. Order carnitine, total and free at baseline and again at 6 weeks — not at two, because the pool falls on the timescale the rodent pre-treatment periods imply Savic 2021 Đurašević 2021. The whole pharmacology is an L-carnitine lowering effect Dambrova 2016, so a flat carnitine is a flat drug: either the dose is too low or the capsule is not what it says. No other compound on this site has a mechanism this cleanly checkable for the price of one test.

2. TMAO should fall, and it is the one unambiguous benefit here. Gut conversion of carnitine is the main dietary route to trimethylamine-N-oxide, and meldonium reduces TMAO Dambrova 2016. Draw TMAO at baseline and 8 weeks, holding red meat and any carnitine supplement constant across the window, because both drive it harder than this will. A fall is the expected result; it is also a reduction in a cardiovascular risk marker produced by depleting a nutrient, which is a trade rather than a free win.

3. Endurance performance should get worse, not better, at low intensity — and this cuts hard against the compound. Long-duration submaximal exercise runs substantially on long-chain fatty acid oxidation, and that pathway requires the carrier this drug deliberately depletes Dambrova 2016. The published cardiac benefit is an ischemic one: more ATP per mole of oxygen when oxygen is scarce Savic 2021. A healthy athlete at steady state is not oxygen-limited in that sense, and the same rat data show the effect collapsing from 3.1-fold to 1.2-fold in a non-diabetic heart. The falsification is a fixed submaximal effort at a fixed heart rate, timed before and after 6 weeks; the mechanism predicts no gain and possibly a loss at the long, easy end.

4. HbA1c and fasting insulin are the sanity check on the substrate switch. The drug pushes tissue toward glucose oxidation Dambrova 2016 Savic 2021. Draw HbA1c and fasting insulin at baseline and 12 weeks. A small fall would be consistent with the mechanism; a rise would mean glucose is being spared rather than burned and would be worth taking seriously, because nobody has measured this in a non-diabetic human at all.

What nobody has tested yet

Five experiments. The first is the one this site’s own readership could complete in a season.

1. Nobody has published a human carnitine dose-response for meldonium at over-the-counter doses. Serum free and total carnitine is a routine assay. Ten people at 500 mg a day and ten at 1,000 mg, drawn at 0, 3, 6 and 12 weeks, would establish what fraction of the pool actually falls at the doses people take — which is the quantity every claim about this drug depends on and which nobody has measured outside a clinical setting.

2. Nobody has tested whether it impairs fat oxidation during exercise. Its own mechanism predicts it should Dambrova 2016. Indirect calorimetry during a fixed submaximal effort, before and after four weeks, gives a respiratory exchange ratio — a direct readout of the fuel being burned. It is a single morning in a laboratory and it would settle whether the most widely believed claim about this compound is backwards.

3. Nobody has published the carnitine repletion time course after stopping. The washout determines how long the metabolic effect lasts and how long the drug remains detectable in an athlete Pușcaș 2024. Serial draws in ten people for twelve weeks after a course would produce both curves at once, and neither exists in the indexed record.

4. Nobody has studied the interaction with L-carnitine supplementation. People take both, sometimes in the same stack. They are directly antagonistic: one depletes the pool through the hydroxylase and OCTN2, the other refills it and competes at the same transporter Dambrova 2016. Whether supplementation abolishes the drug’s effect, is blocked by it, or simply wastes both is unmeasured, and it is a two-arm study.

5. Nobody has repeated the PDH flux measurement in a healthy human heart. Hyperpolarized magnetic resonance has been done in people. The rat result — 3.1-fold in disease, 1.2-fold in health Savic 2021 — makes a specific, testable prediction about who this drug helps, and confirming it in humans would either justify the cardiac indication properly or end the performance claim.

Meldonium — its own safety story, not its class's

The class block on this page is written for metabolic compounds generally. Five things below belong to a drug whose mechanism is deliberate nutrient depletion.

1. The dose-limiting risk is carnitine deficiency, because carnitine deficiency is the mechanism. This is not an off-target concern — the drug is described in terms of its L-carnitine lowering effect Dambrova 2016, and the recognized clinical picture of low carnitine is muscle weakness, exercise intolerance, impaired ketogenesis during fasting, and in severe genetic forms cardiomyopathy. Anyone taking this while also fasting, in a caloric deficit, or training long and low-intensity is stacking three demands on the pathway being blocked. Carnitine, total and free is the monitoring test, and it is monitoring the intended effect.

2. Anyone drug-tested should treat this as disqualifying, and the pharmacology is why a late stop does not help. Meldonium has been on the WADA S4 list since 2016 Pușcaș 2024. Because the effect and the compound both persist on the slow timescale of a tissue metabolite pool rather than the fast one of a plasma half-life, stopping shortly before a test is not a strategy. That reasoning is the mechanism’s, not a published excretion study’s.

3. The published animal doses are far above the human protocol, and that cuts both ways. 100 mg/kg and 300 mg/kg daily in rats Savic 2021 Đurašević 2021 scale to roughly 1.1 to 3.4 grams a day in a human. The card lists 250 to 1,000 mg. So the human dose is safer than the animal literature and also may be too low to reproduce it — the efficacy and the safety argument have to be made at the same exposure and usually are not.

4. The liver deserves a test, because it is a study organ for this drug. One of the two rodent studies behind this page is specifically about hepatic ischemia/reperfusion injury, with the drug given at 300 mg/kg daily for four weeks beforehand Đurašević 2021. Draw a CMP at baseline and at 12 weeks. There is no signal in the human record to react to; this is measuring an organ the research has pointed at rather than responding to a warning.

5. Its regulatory position, stated precisely. Licensed for ischemic heart disease in several Eastern European countries, with decades of clinical use behind that; never assessed by the FDA or EMA; on the WADA prohibited list since 2016 Pușcaș 2024. That is a genuinely different evidentiary position from ‘research chemical’ and also from ‘approved drug’, and the honest version is the long one rather than either short one.

Sources read for this page

• Dambrova M, et al. Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacological Research 2016 · PMID 26850121
• Savic D, et al. Hyperpolarized magnetic resonance shows that the anti-ischemic drug meldonium leads to increased flux through pyruvate dehydrogenase in vivo resulting in improved post-ischemic function in the diabetic heart. NMR in Biomedicine 2021 · PMID 33458907
• Đurašević S, et al. The effects of meldonium on the acute ischemia/reperfusion liver injury in rats. Scientific Reports 2021 · PMID 33446709
• Pușcaș A, et al. Meldonium Supplementation in Professional Athletes: Career Destroyer or Lifesaver?. Cureus 2024 · PMID 39092347

Meldonium — safety, predicted from mechanism

Meldonium — interference & stacking

Bloodwork to run alongside Meldonium

Baseline first, then again at 8–12 weeks.

The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.

Check results you already have → · All 103 markers A–Z

Meldonium — frequently asked questions

Meldonium inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Meldonium is used for

Meldonium appears under 2 goals in the goal router.

Related Metabolic & Fat Loss compounds

← Explore the full Protocol Vault

↑ Back to on this page